Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective biomarker-based trial in metastatic castration-resistant prostate cancer
2019-004817-15Phase 2Completed
- Sponsor
- GZA
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabazitaxel, docetaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by GZA. Primary endpoint: Progression-free survival in poor prognosis biomarker group after protocol-directed therapy switch. Started Feb 2020; status: completed.
02
Drugs
cabazitaxeldocetaxelabirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-004817-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004817-15.